On July 17, 2024, Trifolium Bio-pharmaceutical Co., Ltd. ("Trifolium Bio-B") resubmitted the monthly report of securities changes ending on April 30, 2024. The report shows that the company's legal/registered capital stock remained at 2,000,000,000 shares with a face value of $0.0001 per share, totaling $200,000. The issued shares (excluding treasury shares) increased from 1,296,995,429 shares at the end of last month to 1,297,047,429 shares, an increase of 52,000 shares. The increase was due to the exercise of stock options this month under the pre-IPO stock option plan, resulting in an increase of 52,000 common shares, while 92,000 share options expired. 6,993,573 share options have expired under the post-IPO share option plan. The company confirms that all securities issuances have been authorized by the board of directors and comply with relevant listing rules and laws.

On July 17, 2024, Trifolium Bio-pharmaceutical Co., Ltd. ("Trifolium Bio-B") resubmitted the monthly report of securities changes ending on April 30, 2024. The report shows that the company's legal/registered capital stock remained at 2,000,000,000 shares with a face value of $0.0001 per share, totaling $200,000. The issued shares (excluding treasury shares) increased from 1,296,995,429 shares at the end of last month to 1,297,047,429 shares, an increase of 52,000 shares. The increase was due to the exercise of stock options this month under the pre-IPO stock option plan, resulting in an increase of 52,000 common shares, while 92,000 share options expired. 6,993,573 share options have expired under the post-IPO share option plan. The company confirms that all securities issuances have been authorized by the board of directors and comply with relevant listing rules and laws.